Table 2.

Prevalence, consequence and treatment of myelosuppression and FN in the study and control groups, and in long-acting and short-acting G-CSF users

	Chemotherapy cycles in study group (n=182)	Chemotherapy cycles in control group (n=483)	P value	Chemotherapy cycles of long-acting G-CSF utilisation (n=258)	Chemotherapy cycles of only short-acting G-CSF utilisation (n=347)	P value
Short-acting G-CSF utilisation, n (%)	79 (43.4%)	230 (54.4%)	0.013	95 (36.8%)	214 (61.7%)	<0.001
Doses, mean±SD	1.0±1.7	2.0±2.6	<0.001	0.8±1.6	2.3±2.7	<0.001
Clinical visits, mean±SD
Visits to ER	0.3±0.9	1.0±1.8	<0.001	0.5±1.2	1.0±1.8	<0.001
Visits to outpatient clinics	1.8±1.3	2.5±1.4	<0.001	2.0±1.3	2.5±1.5	<0.001
All visits	2.1±1.7	3.5±2.5	<0.001	2.5±1.9	3.5±2.6	<0.001
CBC times, mean±SD	5.0±1.9	5.3±2.1	0.192	4.9±2.0	5.4±2.1	0.003
FN, n (%)	5 (2.7%)	33 (7.8%)	0.019	7 (2.7%)	31 (8.9%)	0.002
Lasting duration (day), mean±SD	1.8±0.8 (n=5)	1.3±0.6 (n=33)	0.289	1.7±0.8 (n=7)	1.3±0.6 (n=31)	0.171
Admission for FN, n (%)	3/5 (60%)	22/33 (66.7%)	0.567	4/7 (57.1%)	21/31 (67.7%)	0.451
Antibiotics for FN, n (%)	5/5 (100.0%)	27/33 (81.8%)	0.401	7/7 (100.0%)	25/31 (0.267%)	0.267
Myelosuppression, n (%)
All	79 (43.4%)	292 (69.0%)	<0.001	113 (43.8%)	258 (74.4%)	<0.001
Grade 3/4	36 (19.8%)	174 (41.1%)	<0.001	47 (18.2%)	163 (47.0%)	<0.001
Grade 4	12 (6.6%)	73 (17.3%)	<0.001	15 (5.8%)	70 (20.2%)	<0.001
G-CSF-associated pain, n (%)	60/182 (33.0%)	200/423 (47.3%)	0.001	96/223 (43.0%)	164/221 (74.2%)	<0.001
VAS, mean±SD	1.8±2.6	1.4±2.0	0.214	1.7±2.4	1.4±2.0	0.150
Skin rash, n (%)	4/182 (2.2%)	6/421 (1.4%)	0.355	5/258 (1.9%)	5/347 (1.4%)	0.434
Delay of chemotherapy, n (%)	17 (9.3%)	50 (11.8%)	0.373	23 (8.9%)	44 (12.7%)	0.144
Delayed days, mean±SD	0.5±2.2	0.5±1.9	0.930	0.4±2.0	0.5±1.9	0.162

CBC, complete blood count; ER, emergency room; FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; VAS, visual analogue scale.